Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5519855 | 0.92 | MAPT (0.56) | MAPTCRHBPCRHR2L3MBTL1KCNH2 | |
| SCHEMBL2564281 | 0.83 | TDP1 (0.56) | MAPTCRHBPCRHR2L3MBTL1KCNH2 | |
| SCHEMBL2072900 | 0.83 | ALDH1A1 (0.54) | MAPTCRHBPCRHR2KCNH2PTGS2 | |
| SCHEMBL31520919 | 0.82 | CHRNB2 (0.62) | MAPTL3MBTL1PTGS2ALDH1A1LMNA | |
| SCHEMBL21104158 | 0.81 | MAPT (0.53) | MAPTCRHBPCRHR2L3MBTL1KCNH2 | |
| SCHEMBL6138558 | 0.81 | MAPT (0.57) | MAPTCRHBPCRHR2L3MBTL1KCNH2 | |
| SCHEMBL21104434 | 0.81 | MAPT (0.53) | MAPTCRHBPCRHR2L3MBTL1KCNH2 | |
| SCHEMBL6228523 | 0.80 | MAPT (0.65) | MAPTL3MBTL1KCNH2DRD2DRD4 | |
| SCHEMBL116052 | 0.80 | MAPT (0.60) | MAPTKCNH2DRD2DRD4DRD3 | |
| SCHEMBL13251238 | 0.79 | MAPT (0.58) | MAPTCRHBPCRHR2L3MBTL1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976555-A2 | DRUG-POLYMER CONJUGATES | Pharmaessentia Corp. (TW) | 2008-10-08 | — | — | EP | disclosed |
| US-20070185135-A1 | Drug-Polymer Conjugates | PHARMAESSENTIA CORP. | 2007-08-09 | — | — | US | disclosed |
| WO-2007079404-A2 | DRUG-POLYMER CONJUGATES | PHARMAESSENTIA CORP. (TW) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185135-A1 | Drug-Polymer Conjugates | LNPEP, MSN, ANPEP | MAPT 1617/4885CRHBP 287/4885CRHR2 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.